About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Anticoagulants May Not Be Associated With Higher Risk of Bleeding

by Julia Samuel on October 19, 2017 at 7:23 PM
Font : A-A+

New Anticoagulants May Not Be Associated With Higher Risk of Bleeding

For many years, warfarin has been the main anti-clotting drug used to treat venous thromboembolism (VTE). But a new group of drugs (known as direct oral anticoagulants or DOACs) is now being used as an alternative to warfarin because patients don't need regular tests to check if they have the right amount of drug in their bloodstream.

Recent trials have shown the similar effectiveness and a reduced or similar risk of major bleeding complications for DOACs compared with warfarin. However, clinical trials involve a highly selected group of patients, so the rate of safety events such as major bleeding reported in trials often does not reflect those seen in everyday clinical practice.

Advertisement


So a research team based in Canada set out to determine the safety of DOAC use compared with warfarin use in adults diagnosed with VTE between 1 January 2009 and 31 March 2016.

Using healthcare data from six jurisdictions in Canada and the United States, they identified 59,525 adults (12,489 DOAC users and 47,036 warfarin users) with a new diagnosis of venous thromboembolism and a prescription for a DOAC or warfarin within 30 days of diagnosis.
Advertisement

Participants were followed up for an average of 85 days, during which time hospital admissions or emergency department visits for major bleeding and deaths from all causes within 90 days after starting treatment were recorded.

Demographic factors, the presence of other conditions, and history of major bleeding were also taken into account to minimise bias.

Of the 59,525 participants, 1,967 (3.3%) had a major bleed and 1,029 (1.7%) died during the follow-up period.

The risk of major bleeding was similar for DOACs compared with warfarin use. Bleeding rates at 30 days ranged between 0.2% and 2.9% for DOACs and 0.2% and 2.9% for warfarin. Bleeding rates at 60 days ranged between 0.4% and 4.3% for DOACs and 0.4% and 4.3% for warfarin.

No difference was found in the risk of death for DOACs compared with warfarin use. Results remained unchanged after further analyses, including when a longer period of follow-up (180 days) was used.

The authors point out that this is an observational study, so no firm conclusions can be drawn about cause and effect, and say they cannot rule out the possibility that their results may be due to other unmeasured (confounding) factors.

Further studies are also needed to understand the safety of DOACs over the longer term and among patients with advanced chronic kidney disease, they add. Nevertheless, they conclude: "This large multicentre, population-based study suggests that DOAC use is not associated with higher major bleeding risk in venous thromboembolism."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Resting Heart Rate
Is COVID-19 Vaccination during Pregnancy Safe?
Sensory Processing Disorder (SPD)
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Anticoagulants von Willebrand Disease Pulmonary Embolism Hemophilia Common Side Effects of Anticoagulants / Blood Thinners 

Recommended Reading
Novel Oral Anticoagulant Prescriptions Soar, Replacing Warfarin
Warfarin is facing competition, after being a standard treatment for atrial fibrillation for a long ...
Prediction of Warfarin Dose in Patients of African Ancestry Enabled by Genetic Marker
A study published online in The Lancet has revealed that a new genetic marker promises to bet...
Genetic Testing Helps Set Safe Dose of Blood Thinner Warfarin
Warfarin is very effective in preventing blood clots, but it's challenging to regulate. Genetic ......
Not Interrupting Warfarin Therapy During Cardiac Surgery Reduces Risk of Bleeding
A new study reveals that not interrupting warfarin treatment at the time of cardiac device surgery ....
Anticoagulants
Anticoagulants prevent the clotting of blood in our body. They are administered orally or via ......
Common Side Effects of Anticoagulants / Blood Thinners
The main side effect of anticoagulants or blood thinners is bleeding. Others include reduced platele...
Hemophilia
Hemophilia is a rare single gene, X- linked disorder, which tends to run in families....
Pulmonary Embolism
Pulmonary embolism (PE) is a complication that results from a block in the main artery supplying the...
von Willebrand Disease
von Willebrand's Disease (vWD) is an autosomal dominant inherited bleeding disorder that occurs from...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use